ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Possible substitutions for hypersensitivity reactions to taxanes in neoadjuvant breast cancer regimens

Possible substitutions for hypersensitivity reactions to taxanes in neoadjuvant breast cancer regimens
Reaction occurred to Switch to
Paclitaxel 80 to 90 mg/m2 weekly Nabpaclitaxel 100 mg/m2 weekly*
Paclitaxel 175 mg/m2 every two weeks Docetaxel 75 mg/m2 every three weeks
Docetaxel every three weeks Paclitaxel 175 mg/m2 every two weeks; paclitaxel 80 mg/m2 weekly; or nabpaclitaxel 175 mg/m2 every two weeks
Docetaxel 75 mg/m2, in combination with cyclophosphamide 600 mg/m2 every three weeks Doxorubicin 60 mg/m2 and cyclophosphamide 100 mg/m2 every two weeksΔ
CALGB: Cancer And Leukemia Group B.
* As paclitaxel and nabpaclitaxel may not be equivalent on a mg-by-mg basis due to the larger volume of distribution of nabpaclitaxel, we favor using this slightly higher dose of nabpaclitaxel, noting that this is still below the doses that have been associated with increased toxicity.
¶ Docetaxel cannot safely be administered every two weeks due to a high rate of dermatologic toxicity with that schedule.
Δ If there is a contraindication to administration of an anthracycline, we instead opt for sequential administration of single-agent paclitaxel or nabpaclitaxel, either weekly or every two weeks, followed by single-agent cyclophosphamide at 600 mg/m2 every two weeks, according to CALGB 9741.[1]
References:
  1. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003; 21:1431.
Graphic 127065 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟